

ADSTILADRIN may help you KEEP your bladder

ADSTILADRIN is the **FIRST** and **ONLY** FDA-approved gene therapy delivered directly in the bladder for high-risk non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ, with or without papillary tumors, when Bacillus Calmette-Guérin (BCG) doesn't work.

ADSTILADRIN IS



A **localized gene therapy** that may help you keep your bladder



A **monotherapy**, meaning it works by itself to treat NMIBC



Delivered **directly to the bladder**, potentially reducing side effects throughout the body

NMIBC is the most common type of bladder cancer

Bladder **removal** may be required after BCG stops working

ADSTILADRIN IS NOT

Chemotherapy or BCG treatment



Changing your genes or impacting your **whole body**



A treatment that may require you to **change** doctors



EFFECTIVENESS

AT 3 MONTHS



More than half of the people in a clinical study had a complete response (with no signs of high-grade bladder cancer) after just 1 dose (n=50)

FROM 1 YEAR OUT TO 5 YEARS

Of the people who received at least 1 dose of ADSTILADRIN:

AT 1 YEAR



were estimated to **keep their bladder**

OUT TO 5 YEARS



Nearly half were estimated to **keep their bladder**



did not progress to muscle-invasive bladder cancer, even if their cancer didn't go away completely (based on results from a transurethral resection of bladder tumor) (n=103/107)

SAFETY

AT 1 YEAR

Most side effects (75%) were mild

and went away after a median of **just 2 days***

3 people stopped treatment due to side effects

OUT TO 5 YEARS

No new side effects

were reported

No deaths

due to treatment-related side effects



CONVENIENCE



Dosing is just

ONCE EVERY 3 MONTHS

ADSTILADRIN may be given by **YOUR** doctor, just like BCG. Dosing takes at least **1 HOUR**, but you're in and out the **SAME DAY**

*Except for fatigue and frequent daytime urination.

Please see Important Safety Information on next page and full Prescribing Information.



STIL DOING IT MIKE'S WAY

Mike, an actual patient treated with **ADSTILADRIN** who became **cancer free**

“Finding out that I was cancer free was the happiest and most joyful feeling I've ever experienced.”

Watch Mike's story at adstiladrin.com

Ferring is here to support you throughout treatment

Access helpful information and resources, and sign up for updates at adstiladrin.com

INDICATION

ADSTILADRIN is a treatment for adults who have all the following:

- High-risk non-muscle-invasive bladder cancer (NMIBC)
- Cancer that is not responding to Bacillus Calmette-Guérin (BCG) therapy
- Carcinoma in situ (CIS) with or without other high-grade tumors

IMPORTANT SAFETY INFORMATION

Who should not receive ADSTILADRIN?

Do not receive ADSTILADRIN if you have a sensitivity to interferon alfa or any of its components.

What is the most important information I should know about ADSTILADRIN?

Individuals who are immunosuppressed or immune-deficient should not prepare, administer, receive or come into contact with ADSTILADRIN.

What should I tell my healthcare provider?

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of ADSTILADRIN?

The most common side effects of ADSTILADRIN include:

Urinary discharge, fatigue, bladder spasm, urgency to urinate, and blood in your urine.

These are not all the possible side effects of ADSTILADRIN. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.fda.gov/medwatch or call 1-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING.

What other information should I know about using ADSTILADRIN?

For 2 days following treatment, voided urine should be disinfected for 15 minutes with an equal volume of bleach before flushing.

For more important information, call 1-888-337-7464.

Please see full Prescribing Information.



©2025 Ferring. ADSTILADRIN, Ferring and the Ferring Pharmaceuticals logo are trademarks of Ferring.
US-ADST-2400310 v1 01/25

 **ADSTILADRIN**[®]
(nadofaragene firadenovec-vncg)
suspension, for intravesical use / 3 x 10¹¹ viral particles/mL